熱點掃描 | 港股反彈,三指齊漲
uSMART盈立智投1月26日消息,截止發稿,港股三大指數齊漲,恆生指數漲0.38%,報24337.54點,成交額560.59億;恆生科技指下跌1.07%,報5611.55點,成交額111.40億;紅籌指數上漲0.71%報4177.48點,成交額25.65億。
綠電新能源板塊漲幅居前,京城機電股份漲超13%、龍源電力漲超6%;
科技板塊多數上漲,快手板塊漲5.97%、騰訊控股漲1.2%;
抗疫概念走低,百濟神州、藥明生物跌近5%、三葉草生物跌超4%;
熱門股
恆騰網絡盤中衝高超10%後回落,現漲6%;
多家機構持續唱多港口航運板塊22年業績,該板塊內多數上漲,太平洋航運漲超5%、中遠海控漲近3%.
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.